Search Results for: mirgaine day of action – Page 3
Novartis announces AMG 334 significantly reduces patients’ monthly migraine days in phase II study of chronic migraine prevention
Phase II 20120295 study of AMG 334 met primary endpoint, confirming efficacy and safety in patients with chronic migraine over 12 weeks of treatment Migraine is a leading cause of disability, affecting more than 10% of people worldwide – within the overall migraine population, people with chronic migraine experience the greatest impact on daily activities
“Green light” to Lilly’s monoclonal antibody to migraine
Eli Lilly announces that the European Commission (EC) has approved the commercialization of galcanezumab ( Emgality ) as a prophylactic treatment of migraine in adults suffering from at least four days of migraine per month . Galcanezumab is a humanized monoclonal antibody that binds to the peptide related to the calcite gene (CGRP, for its acronym in English) associated with episodes
Novartis’ Migraine prevention therapy is closer to being approved
Friday, June 1, 2018, at 15:45 Novartis has announced that the European Medicines Agency (EMA) Committee on Human Use Medicines (CHMP) has recommended Aimovig (erenumab) approval to prevent migraine in adults suffering at least 4 days of migraine per month. The World Health Organization (WHO) has mentioned migraine as one of the top ten causes
One Tough Challenge: Motherhood with Migraines
Let me set the scene of motherhood with migraines : a Monday evening in late January. My husband had been working like a dog for over a week and I had barely seen him in days. The kids were just getting over their latest in a series of winter illnesses and they were post-sick exhausted
EMHA for Media
For Media Raising awareness and spreading reliable knowledge on migraine. NEWS Read our latest news selected for you. Women and Migraine: Bringing women out of the shadows EHA March 23, 2021 INDUSTRY News The Migraine Alliance, Call to Action: MEPs present their coalition to support EMHA’s advocacy campaign. EHA November 4, 2020 Campaign Events Migraine:
Cluster Headache vs. Migraine
Cluster headaches and migraines both cause pain, but they are two different conditions. A cluster headache is a headache that occurs several times in a day, and it is short in length and very painful. Cluster headaches may only affect one side of the head and pain is usually felt around the eyes. They can
Under the hat
The European Headache Federation (EHF) and the European Migraine Headache Alliance (EMHA) are pleased to announce the 21st March as the first Cluster Headache Day as part of the ‘What’s the Under the Hat?’ public awareness campaign. Cluster headache is one of the worst pains known to man and affects up to 4 in 1,000
EMHA for POLICY MAKERS
For Policy Makers. Making migraine a European health, social and research priority. EMHA CALL TO ACTION Migraine in Europe Time to act now! Migraine is a neglected neurological disease that affects over 41 million people in the European Union (EU). It is labelled as the second leading cause of disability in the world and the
Positive Phase III data for migraine drug Fremanezumab
Positive results from a Phase III HALO study of fremanezumab, an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody investigational treatment for the prevention of migraine, have been announced by Israel-based Teva Pharmaceutical Industries (NYSE: TEVA). In the chronic migraine (CM) study, patients treated with fremanezumab experienced statistically-significant reduction in the number of monthly headache days of
